1. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. Issue 4 (22nd July 2019) Authors: Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine; Michielin, Francesca; James, Ian; Ceppi, Maurizio; Hasmann, Max; We... Journal: ESMO open Issue: Volume 4:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Issue 8 (26th May 2016) Authors: Urup, Thomas; Michaelsen, Signe Regner; Olsen, Lars Rønn; Toft, Anders; Christensen, Ib Jarle; Grunnet, Kirsten; Winther, Ole; Broholm, Helle; Kosteljanetz, Michael; Issazadeh-Navikas, Shohreh; Poulsen, Hans Skovgaard; Lassen, Ulrik Journal: Molecular oncology Issue: Volume 10:Issue 8(2016:Oct.) Page Start: 1160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Issue 5 (18th March 2020) Authors: Urup, Thomas; Gillberg, Linn; Kaastrup, Katja; Lü, Maya Jeje Schuang; Michaelsen, Signe Regner; Andrée Larsen, Vibeke; Christensen, Ib Jarle; Broholm, Helle; Lassen, Ulrik; Grønbæk, Kirsten; Poulsen, Hans Skovgaard Journal: Molecular oncology Issue: Volume 14:Issue 5(2020) Page Start: 964 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS. (11th November 2019) Authors: Eibye, Simone; Hasselbalch, Benedikte; Marie Svane, Inge; Reker Hadrup, Sine; Rønn Olsen, Lars; Skjoeth-Rasmussen, Jane; Scheie, David; Østrup, Olga; Skovgaard Poulsen, Hans; Lassen, Ulrik Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. (7th February 2018) Authors: Toft, Anders; Urup, Thomas; Christensen, Ib Jarle; Michaelsen, Signe Regner; Lukram, Babloo; Grunnet, Kirsten; Kosteljanetz, Michael; Larsen, Vibeke Andrée; Lassen, Ulrik; Broholm, Helle; Poulsen, Hans Skovgaard Journal: Cancer investigation Issue: Volume 36:Number 2(2018) Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical trial allocation in multinational pharmaceutical companies – a qualitative study on influential factors. Issue 3 (19th May 2017) Authors: Dombernowsky, Tilde; Haedersdal, Merete; Lassen, Ulrik; Thomsen, Simon F. Journal: Pharmacology research & perspectives Issue: Volume 5:Issue 3(2017) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Combining PARP inhibition with PD-1 inhibitors. Issue 9 (September 2019) Authors: Lassen, Ulrik Journal: Lancet oncology Issue: Volume 20:Issue 9(2019) Page Start: 1196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. (October 2022) Authors: Lazar, Vladimir; Raynaud, Jacques; Magidi, Shai; Bresson, Catherine; Martini, Jean-François; Galbraith, Susan; Wunder, Fanny; Onn, Amir; Batist, Gerald; Girard, Nicolas; Lassen, Ulrik; Pramesh, C. S.; Al-Omari, Amal; Ikeda, Sadakatsu; Berchem, Guy; Blay, Jean-Yves; Solomon, Benjamin; Felip, Enriq... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS. (12th November 2021) Authors: Maarup, Simone; Skadborg, Signe; Borch, Annie; Draghi, Arianna; Hasselbalch, Benedikte; Østrup, Olga; Scheie, David; Skjoeth-Rasmussen, Jane; Law, Ian; Svane, Inge Marie; Poulsen, Hans; Hadrup, Sine; Lassen, Ulrik Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CTIM-23. EVIDENCE OF T CELL ACTIVATION AND INTRATUMORAL NIVOLUMAB-PRESENCE IN GLIOBLASTOMA PATIENTS TREATED WITH NIVOLUMAB AND BEVACIZUMAB. (12th November 2021) Authors: Skadborg, Signe; Maarup, Simone; Draghi, Arianna; Borch, Annie; Svane, Inge Marie; Hasselbalch, Benedikte; Poulsen, Hans; Lassen, Ulrik; Hadrup, Sine Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗